Scarica l'app Stockscreener
27.42
1.54%
-0.43
Pre-mercato:
27.47
0.05
+0.18%
Precedente Chiudi:
$27.85
Aprire:
$27.9
Volume 24 ore:
57,599
Relative Volume:
0.53
Capitalizzazione di mercato:
$137.07M
Reddito:
$34.77M
Utile/perdita netta:
$-74.04M
Rapporto P/E:
-3.4208
EPS:
-8.0157
Flusso di cassa netto:
$-79.76M
1 W Prestazione:
-0.44%
1M Prestazione:
+236.03%
6M Prestazione:
+197.24%
1 anno Prestazione:
-51.68%
Intervallo 1D:
$27.31
$28.36
Intervallo di 1 settimana:
$27.30
$28.36
Portata 52W:
$5.21
$70.73
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Nome
Mersana Therapeutics Inc
Settore
Industria
Telefono
617-498-0020
Indirizzo
840 MEMORIAL DRIVE, CAMBRIDGE
Confronta MRSN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
27.42 | 139.22M | 34.77M | -74.04M | -79.76M | -8.0157 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-06 | Iniziato | William Blair | Outperform |
| 2024-11-15 | Ripresa | Citigroup | Buy |
| 2024-03-19 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2024-02-29 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-02-29 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-02-29 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-12-04 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-07-28 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-07-27 | Downgrade | Citigroup | Buy → Neutral |
| 2023-07-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-07-27 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-07-27 | Downgrade | Truist | Buy → Hold |
| 2023-07-27 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-06-16 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-06-15 | Iniziato | Guggenheim | Buy |
| 2023-03-16 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-20 | Iniziato | Citigroup | Buy |
| 2022-11-21 | Iniziato | Truist | Buy |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-08-30 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-31 | Iniziato | Credit Suisse | Neutral |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-04-29 | Iniziato | BTIG Research | Buy |
| 2020-01-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-11 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-11-14 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | Iniziato | Robert W. Baird | Outperform |
| 2018-03-19 | Downgrade | JP Morgan | Overweight → Neutral |
Mostra tutto
Mersana Therapeutics Inc Borsa (MRSN) Ultime notizie
Day One to buy Mersana Therapeutics for $25/share upfront - MSN
Is Mersana Therapeutics Inc. (0M4) stock prepared for digital transitionRate Hike & Daily Growth Stock Investment Tips - Newser
Can Mersana Therapeutics Inc. (0M4) stock stage a strong rebound this quarter - Newser
Can Mersana Therapeutics Inc. (0M4) stock sustain breakout momentumJuly 2025 PreEarnings & High Accuracy Investment Entry Signals - Newser
Why Mersana Therapeutics Inc. (0M4) stock could be next leaderJuly 2025 Opening Moves & Community Consensus Stock Picks - Newser
How Mersana Therapeutics Inc. (0M4) stock compares with top peersQuarterly Earnings Summary & Fast Gain Stock Trading Tips - Newser
Will Mersana Therapeutics Inc. (0M4) stock attract long term capital inflowsJuly 2025 Review & Consistent Income Trade Ideas - Newser
Will Mersana Therapeutics Inc. (0M4) stock deliver compounding returnsQuarterly Trade Report & Breakout Confirmation Alerts - Newser
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of "Reduce" by Brokerages - MarketBeat
Options Flow: How Mersana Therapeutics Inc. (0M4) stock compares with market leadersJuly 2025 Setups & Daily Technical Forecast Reports - BỘ NỘI VỤ
How Mersana’s Acquisition Is Changing the Story and Analyst Outlook for Investors - Yahoo Finance
Halper Sadeh LLC Encourages SEMR, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights - Sahm
HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the MergerEXAS, SEE, CDTX, and MRSN - The Malaysian Reserve
Halper Sadeh LLC Encourages SEE, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Is Mersana Therapeutics Inc. (0M4) stock a buy before new product rolloutJuly 2025 Rallies & Risk Controlled Daily Plans - BỘ NỘI VỤ
ENN Energy Holdings Announces Conditional Privatization Proposal - The Globe and Mail
683 Capital Management, LLC Increases Stake in Mersana Therapeutics Inc. - GuruFocus
Can Mersana Therapeutics Inc. (0M4) stock test all time highsJuly 2025 Macro Moves & Free Reliable Trade Execution Plans - newser.com
Will Mersana Therapeutics Inc. stock outperform Dow Jones indexJuly 2025 Trade Ideas & Safe Capital Growth Stock Tips - newser.com
Is Mersana Therapeutics Inc. (0M4) stock testing key supportEarnings Risk Report & AI Driven Stock Reports - newser.com
Does Mersana Therapeutics Inc. qualify in momentum factor screeningShort Setup & Low Drawdown Momentum Ideas - newser.com
Why Mersana Therapeutics Inc. stock remains a top recommendationEarnings Miss & Free Reliable Trade Execution Plans - newser.com
Earnings visualization tools for Mersana Therapeutics Inc.2025 Risk Factors & Safe Swing Trade Setup Alerts - newser.com
Will Mersana Therapeutics Inc. stock benefit from infrastructure spending2025 Analyst Calls & Safe Entry Point Alerts - newser.com
How Mersana Therapeutics Inc. (0M4) stock reacts to weak economyTrade Exit Summary & Safe Capital Growth Tips - newser.com
Detecting price anomalies in Mersana Therapeutics Inc. with AIWeekly Trade Report & Low Risk Entry Point Guides - newser.com
Using data filters to optimize entry into Mersana Therapeutics Inc.Weekly Investment Summary & Low Risk Entry Point Guides - newser.com
Mersana Therapeutics Inc Azioni (MRSN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.10%
1.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):